Posts

Showing posts with the label cancer

Pectasol C Cancer

Image
A brand of modified citrus pectin called PectaSol-C was shown in preliminary clinical trials to block prostate cancer spread by inhibiting Galectin-3 8. The Original and Only Clinically-Proven Modified Citrus Pectin. Econugenics Pectasol C Modified Citrus Pectin Powder 454 G For Sale Online Ebay They grew prostate cancer cells in petri dishes and added Pectasol-C and found that apoptosis was turned back on in these cells resulting in a 54 kill rate in these cells a strongly significant effect. Pectasol c cancer . How you have it. MCP is a chemically altered form of pectin a substance that is familiar to most cooks. MCP may also stimulate the immune system and lower cholesterol. Results of a Prospective Phase II Study on this MCP is now completing its final arm with additional results further substantiating its proven ability at 145 gday to slow PSA doubling time and halt prostate cancer. In a recent issue of the Journal of the National Cancer Institute Raz and colleagues s

Ocrevus Breast Cancer

Image
Patients should follow standard breast cancer screening guidelines. It is uncertain whether there is any change in the rate of breast cancer with Ocrevus. Relapsing Ms And Primary Progressive Ms Treatment Ocrevus Ocrelizumab Tell your doctor if you are pregnant or plan to become pregnant. Ocrevus breast cancer . Ask your doctor about your specific risk. In clinical trials half a percent of patients with relapsing MS and 23 percent of. In the play-in contest in the East Roches multiple sclerosis drug Ocrevus topped Novartis breast cancer drug Piqray. Ocrevus is the first and only therapy approved for both RMS including clinically isolated syndrome RRMS and active or relapsing SPMS and PPMS with dosing every six months. The New York Times the Associated Press CNN NBC News Fox News. There were 6 breast cancers in the group treated with Ocrevus compared to none in the control groups. The biggest worry he said is a possibly heightened risk of breast cancer among women